The combination of nelfinavir and chemoradiotherapy in phase I and II clinical trials showed acceptable toxicity and promising activity in patients with NSCLC, rectal cancers, and pancreatic cancers [160,161,162,163,164] (Table 2), which frequently express KRAS mutations. This evidence concerns the gene KRAS and non-small cell lung carcinoma.